A new study reveals that cancer-linked mutations found in immune cells may contribute to Alzheimer's disease, suggesting new diagnostic and treatment avenues.
Scientists at ETH Zurich identified a new Alzheimer's trigger and developed an experimental compound that slowed nerve cell loss and extended lifespan in mice.
A UCSF study indicates that current vitamin B12 guidelines may not protect the aging brain, as lower active B12 levels are linked to cognitive issues and brain damage in older adults.
Scientists have identified the enzyme IDOL as a potential new target for Alzheimer's treatment, finding that its removal from neurons significantly reduced amyloid plaques and improved brain resilience in lab studies.